By being vertically integrated and owning all steps of the pharmaceutical development and production process, Accord can bring high quality medicines to patients faster, more economically and with greater efficiency than our rivals.
Accord has one of the most dynamic product pipelines in the pharmaceutical industry. Globally, Accord already boasts a portfolio of over 130 molecules across multiple therapeutic classes. We are committed to building up this number to compete with the largest product ranges in the sector.
In Australia, Accord’s portfolio is principally concentrated on the areas of Oncology and Critical Care. Accord will continue to add products locally to complement and broaden its offering to our Australian customers.